Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

Monica Thakar MD
Assistant Professor
Department of Pediatrics
Division of Hematology/Oncology

OFFICE ADDRESS:
MACC Fund Research Center
8701 Watertown Plank Rd
Milwaukee, WI 53226

CITIZENSHIP:  USA

EDUCATION:
1993 - 1997 BS - Biology, University of South Carolina, Columbia, SC
1997 - 2001 MD, Medical University of South Carolina, Charleston, SC

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
2001 - 2004 Intern and Resident, Pediatrics, University of Chicago, Chicago, IL
2004 - 2007 Fellow, Pediatrics, Hematology-Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA
2007 - 2008 Senior Fellow, Pediatrics, Hematology-Oncology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA

FACULTY APPOINTMENTS:
2008 - 2009 Research Associate, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2008 - 2009 Acting Instructor , Pediatrics, University of Washington, Seattle, WA
2010 - Present Affiliate Member, Fred Hutchinson Cancer Research Center, Seattle, WA
2010 - Present Assistant Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
2007 - 2009 Medical Staff, Seattle Children's Hospital, Seattle, WA
2008 - 2009 Medical Staff, University of Washington, Seattle, WA
2008 - 2009 Medical Staff, Seattle Cancer Care Alliance, Seattle, WA
2010 - Present Medical Staff, Children's Hospital of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:
2007 - 2009 Medical Staff, Seattle Children’s Hospital, Seattle, WA
2008 - 2009 Medical Staff, University of Washington Medical Center, Seattle, WA
2008 - 2009 Medical Staff, Seattle Cancer Care Alliance, Seattle, WA
2010 - Present Medical Staff, Pediatrics, Hematology/Oncology/BMT, Children’s Hospital of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
General Pediatrics
2006
2015
Pediatric Hematology-Oncology
2013
2023
 
Licensure
Number Issue DateExpiration
Medical License - WA
2004
2013
Federal DEA License
2004
2015
Medical License, WI
2010
2015
 
AWARDS AND HONORS:
1993 - 1997 Dean’s List, South Carolina Honors College, University of South Carolina
1993 - 1997 Valedictorian Full-Tuition Scholarship, University of South Carolina
1995 Howard Hughes Undergraduate Research Award in Ecology, University of South Carolina
1997 SC Experimental Program to Stimulate Competitive Research (SC EPSCoR) Grant in Developmental Biology, University of South Carolina
2006 Loan Repayment Award, NIH
2007 Travel Award, American Society of Hematology Annual Meeting
2007 Travel Award, Fanconi Anemia Research Fund Annual Meeting
2007 Fellows’ Research Day Award, Seattle Children’s Hospital
2008 Clinical Research Training Institute Workshop Attendance (declined), American Society of Hematology
2008 Cancer Research Clinical Training Workshop Attendance, American Society of Clinical Oncology/American Association of Cancer Research
2008 Travel Award, Fanconi Anemia Research Fund Annual Meeting
2008 Clinical Training Course Attendance (declined), American Society for Blood and Marrow Transplantation (ASBMT)
2011 - 2012 Clinical Research Scholars Program, Clinical and Translational Research Institute (CTSI)
2011 Travel Award, Fanconi Anemia Research Fund Annual Meeting
2012 Young Investigator Travel Award - 2nd International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation Meeting, NIH
2013 Global Photography Exhibition Award Winner in the Healthcare Category– “Practicing subspecialty care in an underdeveloped country”, MCW Global Health Program
2013 Miltenyi Corporation Breakfast Symposium Speaker – Travel Award, American Society of Blood and Marrow Transplant Research (ASBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR) Tandem Meeting, Salt Lake City, UT
2013 Pediatric Faculty Teacher of the Year (as chosen by Pediatric House Staff), Children's Hospital of Wisconsin
2013 Health Volunteers Overseas Program Volunteer Teaching BMT in Underserved Populations, American Society of Hematology
2014 Travel Award, Pediatric Blood and Marrow Transplant Consortium Annual Meeting, Chicago, IL

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
2005 - Present American Society of Hematology (ASH) (Member)
2006 - 2009 American Society of Clinical Oncology (ASCO) (Associate Member)
2006 - Present American Society for Blood and Marrow Transplantation (ASBMT) (Member)
2007 - 2009 American Association for the Advancement of Science (AAAS) (Sponsored Member)
2008 - Present American Society of Pediatric Hematology-Oncology (ASPHO) (Member)
2008 - Present Pediatric Blood and Marrow Transplant Consortium (PBMTC) (Member)
2008 - Present Children’s Oncology Group (COG) (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Journal Review
2010 - Present Journal of Pediatric Hematology and Oncology
2011 - Present Pediatric Blood and Cancer
2011 - Present Biology of Blood and Marrow Transplantation
2012 - Present Annals of Hematology
2015 - Present Blood

LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2008 - 2009 Protocol Reviewer, Clinical Investigator’s Meeting, Fred Hutchinson Cancer Research Center, Seattle, WA
2008 - 2009 Head, Transplantation Biology/Marrow Failure Monthly Clinical Research Meeting, Fred Hutchinson Cancer Research Center, Seattle, WA
2010 - Present Member, Bone Marrow Transplant QI Program Committee, Medical College of Wisconsin
2010 - 2013 Member, Scholarship Oversight Committee for Sam Milanovich, MD, Medical College of Wisconsin, Pediatric Hematology/Oncology Fellowship Program
2010 - Present Co-Leader, Primary Immunodeficiency Transplant Team, Wisconsin’s newborn screening program
2011 - 2013 Advisor and Mentor, Medical School Discovery Curriculum for Haley Robinson, Medical College of Wisconsin
2013 - Present One of two BMT researchers managing DVL patients and regulatory matters on early-phase clinical trials, Pediatric Clinical Trial Office’s Developmental (DVL) Therapeutics Group, Children’s Hospital of WI (appointed)
2013 - Present Member, Leukemia and Lymphoma Disease Group, Children's Hospital of Wisconsin
2013 - Present Pediatric Representative to MCW’s Cancer Center Committee. Reviews cancer-related clinical trials for scientific integrity prior to IRB submission., Scientific Review Committee, MCW Cancer Center (appointed), Medical College of WI

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
2008 - Present Member, Seattle Non-Malignant Transplant Consortium
2009 - Present Referral expert for evaluation and treatment of Fanconi Anemia, Fanconi Anemia Research Fund
2010 - Present Member, Immune Deficiencies and Inborn Errors of Metabolism Working Group and Writing Committee, CIBMTR
2010 - Present Member, Non-Malignant Marrow Disorders Working Group and Writing Committee, CIBMTR
2010 Co-Chair, Session on Pediatric Alternative Donor Transplantation, American Society of Hematology Annual Meeting, Orlando, FL
2010 Member, Abstract Review Committee for Alternative Donor Transplantation, American Society of Hematology Annual Meeting
2010 - Present Member, Cellular Therapies Working Group, CIBMTR
2011 Study Section grant reviewer, Clinical Research Training Institute (CRTI) , American Society of Hematology
2012 - Present Member , Primary Immune Deficiency Treatment Consortium (PIDTC), Protocol 6902 National Working Group, Primary Immune Deficiency Treatment Consortium (PIDTC),
2013 Study Section grant reviewer, Clinical Research Training Institute (CRTI) , American Society of Hematology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Donor lymphocyte infusions using natural killer cells after transplant
Source:
Midwest Athletes Against Childhood Cancer (MACC) Fund – New faculty recruit start-up funds
Role:
Principal Investigator of Translational Projects
Dates:
1/1/2010 - Present
Direct Funds:
$60,000
 
Title:
Support for Protocol 2230, Miltenyi CliniMACS Disposable Agents
Source:
Miltenyi Corporation
Role:
IND Sponsor/Holder BB IND 13794
Dates:
3/24/2011 - 3/24/2016
Direct Funds:
$294,500 (supplies)
 
Title:
NK cell immunotherapy in relapsed and refractory solid tumors
Source:
American Cancer Society Pilot Research Grant (Thakar/Malarkannan)
Role:
Principal Investigator of new clinical trial
Dates:
7/1/2012 - 12/31/2014
Direct Funds:
$30,000
 
Title:
A Phase I/II trial evaluating NK immunotherapy in relapsed/refractory solid tumors
Source:
Pablove Foundation
Role:
Principal Investigator of new clinical trial
Dates:
7/1/2012 - 6/30/2015
Direct Funds:
$50,000
 
Title:
Support for New Solid Tumor Protocol, Miltenyi CliniMACS Disposable Agents
Source:
Miltenyi Corporation (Thakar)
Role:
IND Sponsor/Holder BB IND 13794
Dates:
2012 - 2015
Direct Funds:
$101,000 ((supplies)
 
Title:
Chimeric Antigen Receptors in natural killer cells
Source:
Midwest Athletes Against Childhood Cancer (MACC) Fund – Novel Initiative (Thakar/Malarkannan)
Role:
Principal Investigator
Dates:
7/1/2013 - 6/30/2015
Direct Funds:
$75,000 (total direct)
 
Title:
Molecular Signature of Inflammation
Source:
National Cancer Institute
Role:
Co-Principal Investigator
Dates:
3/10/2014 - 2/28/2019
 
Title:
NK immunotherapy for the treatment of childhood cancers – Drug-Induced Activation and
Source:
Midwest Athletes Against Childhood Cancer (MACC) Fund
Role:
Principal Investigator
Dates:
7/1/2014 - 6/30/2015
Direct Funds:
$88,149
 
Prior
Peer Review
Title:
Pediatric Oncology Translational Research Program
Source:
NIH/NCI T32 CA09351 (Bernstein)
Role:
Pediatric Hematology-Oncology Fellow
Dates:
7/1/2005 - 6/30/2007
 
Title:
Stem Cell Transplantation: Basic/Clinical Research Sub-Project 1:Allogeneic hematopoietic cell transplantation for nonmalignant diseases
Source:
NIH/NHLBI HL 36444-28
Role:
Investigator - 20% effort
Dates:
8/1/2007 - 11/30/2009
Direct Funds:
$94,645
 
Title:
Nonmyeloablative Hematopoietic Cell Transplantation for Patients with Fanconi Anemia
Source:
Fanconi Anemia Research Foundation
Role:
Principal Investigator of Protocol 2064
Dates:
1/1/2008 - 12/31/2009
Direct Funds:
$81,786
 
Title:
Pilot Project to Support Product Characterization and Immune Reconstitution Studies
Source:
Orin Edson Foundation
Role:
Co-Principal Investigator
Dates:
7/1/2008 - 12/31/2009
Direct Funds:
$24,886
 
Title:
Mixed Hematopoietic Chimerism after Stem Cell Allografts Sub project 3: Mixed Chimerism in the Treatment of Leukemias:
Source:
NIH/NCI CA078902-11
Role:
Investigator
Dates:
8/1/2008 - 1/31/2009
Direct Funds:
$118,102
 
Title:
Stem Cell Transplantation: Basic/Clinical Research Sub-project 2: Nonmyeloblative allografts in DLA-haploidentical dogs: engraftment/GVHD
Source:
NIH/NHLBI HL 36444
Role:
Investigator – 10% effort
Dates:
2/1/2009 - 11/30/2009
Direct Funds:
$231,695
 
Title:
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation-
Source:
Kuni Foundation
Role:
Co-Principal Investigator of Protocol 2230
Dates:
4/1/2010 - 3/30/2011
Direct Funds:
$124,843
 
Title:
Adoptive immunotherapy using natural killer cells
Source:
Rebecca Jean Slye Endowment
Role:
Principal Investigator of new laboratory project
Dates:
1/11/2011 - 12/31/2011
Direct Funds:
$15,000
 
Title:
BMT CTN 0801: A Phase II/III Randomized, Multi-center Trial Comparing Sirolimus plus Prednisone, Sirolimus/ECP plus Prednisone, and Sirolimus Calcineurin Inhibitor plus Prednisone for the treatment of Chronic Graft-versus-Host Disease
Source:
National Marrow Donor Program (NMDP)
Role:
Local Principal Investigator of national BMT protocol
Dates:
1/25/2011 - 12/31/2013
Direct Funds:
$5,620 (pt enrolled)
 
Title:
A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation-
Source:
Hyundai Scholars Program
Role:
Co-Principal Investigator of Protocol 2230
Dates:
2/1/2011 - 12/31/2012
Direct Funds:
$50,000
 
Title:
Adoptive immunotherapy using natural killer cells
Source:
Rebecca Jean Slye Endowment
Role:
Principal Investigator of new laboratory project
Dates:
1/1/2012 - 1/31/2012
Direct Funds:
$20,000
 
Title:
Laboratory application of natural killer cells for adoptive immunotherapy
Source:
Midwest Athletes Against Childhood Cancer (MACC) Fund – Novel Initiative
Role:
Co-Principal Investigator of laboratory and translational projects
Dates:
7/1/2012 - 6/30/2013
Direct Funds:
$63,086
 
Title:
Leukemia: Molecular and Cellular Mechanisms of Pathogenesis and Immunotherapy
Source:
MCW Cancer Center Multi-PI Seed Grant – Advancing a Healthier Wisconsin
Role:
Co-Principal Investigator of Project 3 (Chimeric Antigen Receptors)
Dates:
2012 - 2013
Direct Funds:
$100,000
 
Title:
Cellular and adoptive immunotherapy using hematopoietic cell transplantation and NK cell infusion for the treatment of high-risk pediatric and adult solid tumors: a Phase I/II Study
Source:
Clinical and Translational Science Institute
Role:
Co-Principal Investigator
Dates:
7/1/2013 - 6/30/2014
Direct Funds:
$50,000
 
INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Regional
1. “Major histocompatibility complex: the alphabet soup.” Non-myeloablative transplantation research staff didactic series, Fred Hutchinson Cancer Research Center, Seattle, WA, 7/2008
2. “Non-myeloablative hematopoietic cell transplantation.”, Pediatric Surgery Basic Science Lecture Series, Children’s Hospital of Wisconsin, Children’s Hospital of Wisconsin, Milwaukee, WI, 2/2011
3. , “The role of transplantation for primary immune deficiencies.” , Pediatric Allergy/Immunology Grand Rounds,, Children’s Hospital of Wisconsin, Milwaukee, WI, 5/2011
4. “The Role of Immunotherapy in Hematopoietic Cell Transplantation.” , Pediatric Surgery Basic Science Lecture Series, Children’s Hospital of Wisconsin, Milwaukee, WI, 6/2013
5. “Advances in Hematopoietic Cell Transplantation for Primary Immune Deficiencies.” , Pediatric Allergy/Immunology Grand Rounds, Children's Hospital of Wisconsin, Milwaukee, WI, 2/2014
6. “NK Cell Immunotherapy”, Children’s Research Institute Noon Conference, Children's Hospital of Wisconsin, Milwaukee, WI, 5/2014
 
National
1. HLA-haploidentical hematopoietic cell transplantation for Fanconi Anemia, Collaborator/Multi-Institutional Annual Mixed Chimerism Meeting, Seattle, WA, 5/2007
2. Pre-emptive donor natural killer cell donor lymphocyte infusion early after nonmyeloablative, HLA-haploidentical hematopoietic cell transplantation, Collaborator/Multi-Institutional Annual Mixed Chimerism Meeting, Seattle, WA, 5/2008
3. CD3-Depleted donor lymphocyte infusions after canine MHC-haploidentical nonmyeloablative hematopoietic cell transplantation, Collaborator/Multi-Institutional Annual Mixed Chimerism Meeting, Seattle, WA, 5/2008
4. Invited Participant, Workshop for Transplantation of Bone Marrow Failure and Acute Myeloid Leukemia in Fanconi Anemia,, 20th Annual Fanconi Anemia Research Fund Annual Symposium, Eugene, OR, 10/2008
5. “Harnessing the power of HLA-haploidentical transplantation", Blood Research Institute/Medical College of WI, Milwaukee, WI, 4/2009
6. “Harnessing the power of HLA-haploidentical transplantation", Riley Children’s Hospital/University of Indiana, Indianapolis, IN, 4/2009
7. “Harnessing the power of HLA-haploidentical transplantation” , Vanderbilt University, Nashville, TN, 4/2009
8. “Severe aplastic anemia", Data Managers Conference, American Society of Blood and Marrow Transplantation Annual Meeting, Orlando, FL, 1/2010
9. "Update on Protocol 2230", Collaborator/Multi-Institutional Annual Mixed Chimerism Meeting, Seattle, WA, 5/2010
10. "Update on Protocol 2230", Collaborator/Multi-Institutional Annual Mixed Chimerism Meeting, Seattle, WA, 5/2011
11. "Update on Protocol 2230", Collaborator/Multi-Institutional Annual Mixed Chimerism Meeting, Seattle, WA, 5/2012
12. NK cell adoptive immunotherapy for solid tumors, American Cancer Society Annual Awards and , Milwaukee, WI, 8/2012
13. “Natural killer cell prophylaxis after HLA-haploidentical transplantation", Miltenyi Breakfast Symposia, ASBMT/CIBMTR Tandem Annual Meeting, Salt Lake City, NV, 2/2013
 
International
1. Endocrinopathy in Fanconi Anemia, 1st Annual Brazil Fanconi Anemia Family Meeting and Educational Symposium, Curitiba, Brazil, 11/2009
2. Pediatric Oncology and Transplant Lecture Series, American Society of Hematology/Health Volunteers Overseas, Lima, Peru, 8/2013
 
PEER REVIEWED WORKSHOPS/PRESENTATIONS:
National
1. Thakar MS, Liedel JL, Rubin CM, Brown M, Bacha EA, Kahana MD, FVIIa for Peri-Operative Bleeding in the PICU and NICU, Pediatric Academic Society Meeting, San Francisco, CA, 5/2004
2. Thakar MS, Gooley TA, Santos EB, Storb RF, Sandmaier BM, High-dose methotrexate as part of a novel immunosuppressive regimen in canine MHC-haploidentical hematopoietic cell transplantation, American Society of Hematology Annual Meeting - Poster Presentation, Orlando, FL, 12/2006
3. Thakar MS, Woolfrey AE, Kletzel M, Frangoul H, Pulsipher M, Sandmaier B, Storb, Flowers M, Kurre P, Kiem HP, HLA-matched unrelated donor stem cell transplantation using low-dose total body irradiation and fludarabine for Fanconi Anemia patients with aplastic anemia, Nineteenth Annual Fanconi Anemia Research Fund Scientific Symposium - Poster Presentation, Chicago, IL, 10/2007
4. Thakar MS, Storer B, Chauncey T, MD, Pulsipher M, Maloney D, Storb R, Sandmaier B, Reversal of low chimerism following non-myeloablative hematopoietic cell transplantation using pentostatin and donor lymphocyte infusions, American Society of Hematology Annual Meeting, Atlanta, GA, 12/2007
5. Thakar MS, Storer B, Storb R, Shizuru J. Niederwieser D, Pulsipher M, Sahebi F, Sorror M, Chen Y, Georges G, Maloney D, Woolfrey A, Sandmaier BM, Treatment of pediatric high-risk malignancies using non-myeloablative (NM) hematopoietic cell transplantation (HCT): a multi-institutional experience, American Society of Blood and Marrow Transplantation Tandem Meetings, Orlando, FL, 2/2010
6. Thakar MS, Schuldt K, Malarkannan S. , Lenalidomide augments NKG2D-mediated cytokine/chemokine production from NK cells, NCI Cancer Immunology and Immunotherapy Meeting: Building on Success, Poster Presenter, Bethesda, MD, 9/2011
7. Thakar MS, Schuldt K, Malarkannan S, Lenalidomide augments NKG2D-mediated cytokine production but not cytotoxicity from NK cells, American Society Hematology Annual Meeting Poster Presentation, San Diego, CA, 12/2011
8. Thakar MS, Hari P, Heimfeld S, Keever-Taylor C, Sandmaier B, Donor natural killer cell infusions following non-myeloablative HLA-haploidentical transplantation to augment graft-versus-tumor effects in patients with hematological malignancies, NIH 2nd International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation Meeting Oral and Poster Presentation, Bethesda, MD, 11/2012
9. Thakar MS, Logan B, Pasquini M, McCarthy P, Ho V, Cooke K, Zhu X, Rizzo D, Sorror M, The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases, American Society of Hematology Annual Meeting Oral Presentation, Atlanta, GA, 12/2012
10. Robinson H, Nugent M, Simpson P, Keever-Taylor C, Margolis D, Casper J, Thakar M. , Long-Term Single Center DLI Outcomes Show A Role For Durable Response In High-Risk Pediatric Lymphoid Malignancies, Pediatric Blood and Marrow Transplant Consortium/American Society of Pediatric Hematology Oncology Annual Meeting Poster Presenter, Miami, FL, 4/2013
11. To Condition or Not to Condition?, Pediatric Immune Deficiency Consortium Annual Meeting Poster Presentation, Houston, TX, 5/2013
12. Robinson H, Nugent M, Simpson P, Keever-Taylor C, Margolis D, Casper J, Thakar M. , Long-Term Single Center DLI Outcomes Show A Role For Durable Response In High-Risk Pediatric Lymphoid Malignancies, Midwest Society for Pediatric Research Annual Meeting Poster Presentation, Minneapolis, MN, 10/2013
13. Thakar MS, Walters M, Sandmaier BM, Storb R, Flowers ME, Deeg J, O’Donnell P, Woolfrey A, Kiem HP, Long-Term Follow-Up of Cyclophosphamide-Based In Vivo T-Cell Depletion For HLA-HaploidenticaTransplantation In Fanconi Anemia, Midwest Society for Pediatric Research Annual Meeting Poster Presentation, New Orleans, LA, 12/2013
14. Thakar MS, Bonfim C, Sandmaier BM, O'Donnell P, Ribeiro L, Gooley T, Deeg HJ, Flowers ME, Pasquini R, Storb R, Woolfrey AE, Kiem HP , Updated Experience Using Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion For HLA- Haploidentical Transplantation In Fanconi Anemia , Pediatric Blood and Marrow Transplant Consortium , Chicago, IL, 5/2014
15. Divergent management strategy of two siblings with T cell lymphopenia detected by TREC screen, Pediatric Immune Deficiency Consortium Annual Meeting Poster Presentation, Seattle, WA, 5/2014
 
International
1. Wilbur DS, Hamilin DK, Chyan MK, Thakar MS, Pantelias AA, Santos EB, Pagel JM, Press OW, Sandmaier BM, 211At-Labeling Using Dianionic Decaborate Cage Moieties Provides High Labeling Efficiency and High In Vivo Stability, Workshop on Alpha Emitting Radionucleotides in Therapy, Aachen, Germany, 4/2007
2. Thakar MS, Bonfim C, O’Donnell P, Sandmaier BM, Deeg HJ, Flowers ME, Paquini R, Storb R, Woolfrey A, Kiem HP, Cyclophosphamide-based in vivo T cell depletion for HLA-haploidentical transplantation in Fanconi Anemia, Twenty-third Annual Fanconi Anemia Research Fund Scientific Symposium Poster Presentation, Barcelona, Spain, 10/2011
3. Thakar MS, Kumar P, Kamalakannan R, Schuldt K, Malarkannan S, “IL-27 initiates strong, early NK cell-mediated effector functions in a murine model" , 3rd International Conference on Immunotherapy in Pediatric Oncology Poster Presentation, Frankfurt, Germany, 10/2012
4. Keever-Taylor CA, Jones LA, Heimfeld S, Sandmaier BM, Hari P, Thakar MS, Characteristics of Products for NK Cell Infusion Prepared by CD3 Depletion Followed by CD56 Enrichment: Requirements for Rare Event Analysis, International Society for Cellular Therapy Annual Meeting Poster Presentation, Paris, France, 4/2014
 
COMMITTEE SERVICE:
Medical College
2010 - 2013 Member, Scholarship Oversight Committee for Sam Milanovich, MD, Hematology/Oncology/BMT, Pediatrics, Medical College of Wisconsin
2010 - Present Member, Bone Marrow Transplant QI Program Committee, Medical College of Wisconsin
 
MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
1/2012 MCW Medical Student Lecturer: Tumor and Transplantation Immunity Team-Based Learning (TBL) Module (Bone Marrow Transplant section)
2013 - Present History and Physical Reviewer for M3 Medical Students (Pediatric Clerkship)
2014 - Present Advisor and Mentor, Benjamin Knight (Medical Student)
2014 - Present Medical School Pathways Curriculum – Physician Scientist Small Group Preceptor
 
Resident and Fellow Education
2010 - Present Pediatric Residency Core Curriculum Lecture Series, Pediatric Hematology/Oncology Rotation - Immunodeficiencies
2010 - Present Pediatric Residency Core Curriculum Lecture Series, Pediatric Hematology/Oncology Rotation - Introduction to Bone Marrow Transplantation
2013 - Present Member, Scholarship Oversight Committee for Anna Vinitsky, MD
2014 - Present Member, Pediatric Residency Admissions Committee
2014 - Present Mentor, Nathan Schloemer, MD for Fellowship Project (Immunotherapy/translational)
 
Continuing Medical Education
1/2010 Pediatric Hematology/Oncology/BMT Tumor Board - Non-Myeloablative Transplants
12/2010 Pediatric Hematology/Oncology/BMT Tumor Board - Role of transplantation for refractory Hodgkin Lymphoma
2/2011 Pediatric Surgery Basic Science Lecture Series - Non-myeloablative hematopoietic cell transplantation
5/2011 Pediatric Allergy/Immunology Grand Rounds - The role of transplantation for primary immune deficiencies
6/2011 Pediatric Hematology/Oncology/BMT Tumor Board - "Adoptive immunotherapy in oncology and BMT"
8/2012 Pediatric Hematology-Oncology-BMT Tumor Board Presenter "Hodgkin Lymphoma”
1/2013 “Pediatric Hematology-Oncology-BMT Tumor Board Presenter: "Concept/Plans for Joint Onc-BMT Solid Tumor Protocol”
5/2014 Pediatric Allergy and Immunology Grand Rounds: “Advances in Hematopoietic Cell Transplantation for Primary Immune Deficiencies”
5/2014 Adult BMT Leukemia Research Meeting,“NK Cell Adoptive Immunotherapy"
5/2014 Children’s Research Institute Noon Conference "NK Cell Immunotherapy"
 
EXTRAMURAL TEACHING (e.g. at Marquette, UWM, etc.):
Continuing Medical Education
6/2007 Fred Hutchinson Cancer Research Center, Program in Transplantation Biology, Clinical Research Division Work-in-Progress Seminar - High-dose post-transplant methotrexate as part of a novel immunosuppressive regimen in canine MHC-haploidentical hematopoietic cell transplantation
6/2007 Seattle Children’s Hospital, Division of Pediatric Hematology/Oncology Research Seminar - Canine MHC-haploidentical hematopoietic cell transplantation
7/2008 Fred Hutchinson Cancer Research Center, Non-myeloblative Transplantation Research Staff Didactic Series Presentation - Major histocompatibility complex: the alphabet soup
10/2008 Fred Hutchinson Cancer Research Center, Program in Transplantation Biology, Clinical Research Division Work-in-Progress Seminar - Update of studies in canine MHC-haploidentical non-myeloablative hematopoietic cell transplantation
 

BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Fox CW, Martin JD, Thakar MS, Mousseau TA. Clutch Size Manipulations in Two Seed Beetles, Stator limbatus (horn) and S. beali Johnson: Consequences for Fitness. Oecologia. 1996 Oct;108(1):88-94
2. Fox CW, Thakar MS, Mousseau TA. Egg Size Plasticity in a Seed Beetle: An Adaptive Maternal Effect. The American Naturalist. 1997 Jan;149(1):149-163
3. Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, Kenoyer AL, Pagel JM, Press OW, Storb R, Sandmaier BM. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 2009 Mar 15;69(6):2408-15,PMCID:PMC2657815
4. Thakar MS, Zhang XB, Beard BC, Sale GE, Santos EB, Peterson L, Kiem HP, Sandmaier BM. Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model. Exp Hematol. 2009 Oct;37(10):1157-66,PMCID:PMC2748853
5. Wilbur DS, Thakar MS, Hamlin DK, Santos EB, Chyan MK, Nakamae H, Pagel JM, Press OW, Sandmaier BM. Reagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine. Bioconjug Chem. 2009 Oct 21;20(10):1983-91,PMCID:PMC2888658.
6. Thakar MS, Forman SJ. ASH evidence-based guidelines: is there a role for second allogeneic transplant after relapse? Hematology Am Soc Hematol Educ Program. 2009:414-8
7. Thakar MS, Santos EB, Fricker S, Bridger G, Storb R, Sandmaier BM. Plerixafor-moblized stem cells alone are capable of inducing early engraftment across the MHC-haploidentical canine barrier. Blood. 2010 Jan 28;115(4):916-7,PMCID:PMC2815512
8. Thakar MS, Santos EB, Gooley TA, Sale G, Storb R, Kiem HP, Sandmaier BM. Evaluation of posttransplant methotrexate to facilitate engraftment in the canine major histocompatibility complex-haploidentical nonmyeloablative transplant model. Transplantation. 2010 Jul 15;90(1):14-22,PMCID:PMC2921965
9. Thakar MS, Kurre P, Storb R, Kletzel M, Frangoul H, Pulsipher MA, Leisenring W, Flowers ME, Sandmaier BM, Woolfrey A, Kiem HP. Treatment of Fanconi anemia patients using fludarabine and low-dose TBI, followed by unrelated donor hematopoietic cell transplantation. Bone Marrow Transplant. 2011 Apr;46(4):539-44,PMCID:PMC2976796
10. Rajasekaran K, Chu H, Kumar P, Xiao Y, Tinguely M, Samarakoon A, Kim TW, Li X, Thakar MS, Zhang J, Malarkannan S. Transforming growth factor-beta-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production. J Biol Chem. 2011 Sep 9;286(36):31213-24,PMCID:PMC317306
11. Chen Y, Fukuda T, Thakar MS, Kornblit BT, Storer BE, Santos EB, Storb R, Sandmaier BM. Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complex-haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy. 2011 Nov;13(10):1269-80,PMCID:PMC3195840
12. Malarkannan S, Awasthi A, Rajasekaran K, Kumar P, Schuldt KM, Bartoszek A, Manoharan N, Goldner NK, Umhoefer CM, Thakar MS. IQGAP1: A Regulator of Intracellular Spacetime Relativity. J Immunol. 2012 Mar 1;188(5):2057-63,PMCID:PMC3286039
13. Kumar P, Bartoszek AE, Moran TM, Gorski J, Bhattacharyya S, Navidad JF, Thakar MS, Malarkannan S. High-throughput Detection Method for Influenza Virus. J Vis Exp. 2012 Feb 4;(60)e3623,PMCID:PMC3195840.
14. Verbsky J, Thakar M, Routes J. The Wisconsin approach to newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2012 Mar;129(3):622-7,PMID: 22244594
15. Thakar MS, Bonfim C, Sandmaier BM, O'Donnell P, Ribeiro L, Gooley T, Deeg HJ, Flowers ME, Pasquini R, Storb R, Woolfrey AE, Kiem HP Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol. 2012 Sep;29(6):568-78,PMCID:PMC3622043
16. Kumar P, Bartoszek AE, Moran TM, Gorski J, Bhattacharyya S, Navidad JF, Thakar MS, Malarkannan S High-throughput detection method for influenza virus. J Vis Exp. 2012(60): PMCID: PMC3369630
17. Kumar P, Thakar MS, Ouyang W, Malarkannan S IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol. 2013 Jan;6(1):69-82,PMCID:PMC3835350
18. Ayas M, Saber W, Davies SM, Harris RE, Hale GA, Socie G, Lerademacher J, Thakar M, Deeg HJ, Al-Seraihy A, Battiwalla M, Camitta BM, Olsson R, Bajwa RS, Bonfim CM, Pasquini R, Macmillan ML, George B, Copelan EA, Wirk B, Al Jefri A, Fasth AL, Guinan EC, Horn BN, Lewis VA, Slavin S, Stepensky P, Bierings M, Gale RP Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia. J Clin Oncol. 2013 Apr 1,PMCID: PMC3635221
19. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S Corrigendum: Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol. 2014 Feb;15(2):205,PMCID: PMC3855032
20. Burroughs LM, Nemecek ER, Torgerson TR, Storer BE, Talano JA, Domm J, Giller RH, Shimamura A, Delaney C, Skoda-Smith S, Thakar MS, Baker KS, Rawlings DJ, Englund JA, Flowers ME, Deeg HJ, Storb R, Woolfrey AE Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multi-Center Trial. Biol Blood Marrow Transplant. 2014 Dec;20 (12):1996-2003, PMCID:PMC4324724
21. Abel AM, Schuldt KM, Rajasekaran K, Hwang D, Riese MJ, Rao S, Thakar MS, Malarkannan S IQGAP1: Insights into the function of a molecular puppeteer. Mol Immunol. 2015 Jun;65(2):336-349 PMID: 25733387
 
Books, Chapters, and Reviews
1. Malarkannan S, Awasthi T, Rajasekaran K, Kumar P, Schuldt KM, Bartoszek A, Manoharan N, Goldner NK, Umhoefer CM, Thakar MS. IQGAP1: A Regulator of Intracellular Spacetime Relativity. J Immunol. 2012 Mar 1;188(5):2057-63
2. Kumar P, Rajasekaran K, Palmer JM, Thakar MS, Malarkannan S IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. J Cancer. 2013;4(1):57-65,PMCID:PMC3564247
3. Palmer JM, Rajasekaran K, Thakar MS, Malarkannan S Clinical relevance of natural killer cells following hematopoietic stem cell transplantation. J Cancer. 2013;4(1):25-35,PMCID:PMC3564244
4. Thakar MS, Talano J, Tower R, Kelly M, Burke M. Allogeneic Hematopoietic Cell Transplantation for Childhood Acute Leukemia, Clinical Practice, January 2014.
 
Abstracts
1. Thakar MS, Liedel JL, Rubin CM, Brown M, Bacha EA, Kahana MD. FVIIa for peri-operative bleeding in the PICU and NICU. PAS Annual Meeting Program with Abstracts-on-Line. 2004 May;Abstract #1749:http://www.abstracts2view.com/pasall/view.php?nu=PAS4L1_3128
2. Thakar MS, Gooley TA, Santos EB, Storb RF, Sandmaier BM. High-Dose Methotrexate as Part of a Novel Immunosuppressive Regimen in Canine MHC-Haploidentical Hematopoietic Cell Transplantation. Blood (ASH Annual Meeting Abstracts). 2006 Nov;108:3180
3. Thakar MS, Storer B, Chauncey T, MD, Pulsipher M, Maloney D, Storb R, Sandmaier B. Reversal of Low Chimerism Following Nonmyeloablative Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusions. Blood (ASH Annual Meeting Abstracts). 2007 Nov;110:480
4. Wilbur D, Hamilin D, Nakamae H, Thakar MS, Santos E, Pantelias A, Kenoyer A, Pagel J, Press O, Storb R, Sandmaier B. Comparison of biodistributions, myelosuppression and toxicity in mice of an anti-CD45 antibody labeled with the α-emitters 213Bi or 211At. AACR Meeting Abstracts. 2008 Apr;2008:3160
5. Nakamae H, Wilbur D, Hamlin D, Thakar MS, Santos E, Fisher D, Kenoyer A, Pagel J, Press O, Storb R, Sandmaier B. Evaluation of Toxicity and Tissue Radiation Doses obtained in Mice with an Anti-CD45 Monoclonal Antibody (mAb) labeled with the Alpha-Emitting Radionuclides, Astatine-211 or Bismuth-213. Blood (ASH Annual Meeting Abstracts). 2008 Nov;112:3270
6. Thakar MS, Storer B, Storb R, Shizuru J, Niederwieser D, Pulsipher M, Sahebi F, Sorror M, Chen Y, Georges G, Maloney D, Woolfrey A, Sandmaier B. Treatment of pediatric high-risk malignancies using non-myeloablative (NM) hematopoietic cell transplantation (HCT): a multi-institutional experience. Biology of Blood and Marrow Transplantation. 2010 Feb;16,(2, Suppl 2):S246-S247.
7. Kornblit B, Hwang B, Storer B, Thakar MS, Santos EB, Nash R, Sandmaier B. Peripheral blood stem cell mobilization with single agent plerixafor induces FoxP3 expression in donor T cells and enables durable long term hematopoietic engraftment across mismatched major histocompatibility complex barriers. Blood (ASH Annual Meeting Abstracts). 2011 Dec;118(21):1891
8. Thakar MS, Schuldt K, Bartlett B, Malarkannan S. Lenalidomide augments NKG2D-mediated cytokine production but not cytotoxicity from NK cells. Blood(ASH Annual Meeting Abstracts). 2011 Dec;118(21):1918
9. Wilbur DS, Hamilin DK, Chyan MK, Thakar MS, Pantelias AA, Santos EB, Pagel JM, Press OW, Sandmaier BM. 211At-Labeling Using Dianionic Decaborate Cage Moieties Provides High Labeling Efficiency and High In Vivo Stability. Workshop on Alpha Emitting Radionucleotides in Therapy, Aachen, Germany, April 2007.
10. Thakar MS, Woolfrey AE, Kletzel M, Frangoul H, Pulsipher M, Sandmaier B, Storb, Flowers M, Kurre P, Kiem HP. HLA-matched unrelated donor stem cell transplantation using low-dose TBI and FLU for FA patients with aplastic anemia [abstract]. Nineteenth Annual Fanconi Anemia Research Fund Scientific Symposium. 2007;104.
11. Bonfim C, Thakar MS, Macmillan M, Davies S, Kiem HP, Mehta P, Bitencourt M, Wagner J, Storb R, Pasquini R. Cancer after Hematopoietic Cell Transplantation in Patients with Fanconi Anemia [abstract]. Twentieth Annual Fanconi Anemia Research Fund Scientific Symposium. 2008:78.
12. Thakar MS, Schuldt K, Malarkannan S. Lenalidomide augments NKG2D-mediated cytokine/chemokine production from NK cells. NCI Cancer Immunology and Immunotherapy Meeting: Building on Success. Abstract #92, 2011.
13. Thakar MS, Bonfim C, O’Donnell P, Sandmaier BM, Deeg HJ, Flowers ME, Paquini R, Storb R, Woolfrey A, Kiem HP. Cyclophosphamide-based in vivo T cell depletion for HLA-haploidentical transplantation in Fanconi Anemia. Twenty-third Annual Fanconi Anemia Research Fund Scientific Symposium. 2011: 152.
14. Thakar MS, Kumar P, Kamalakannan R, Schuldt K, Malarkannan S. “IL-27 initiates strong, early NK cell-mediated effector functions in a murine model.” 3rd International Conference on Immunotherapy in Pediatric Oncology, Abstract #45, Oct 2012.
15. Thakar MS, Hari P, Heimfeld S, Keever-Taylor C, Sandmaier B. “Donor natural killer cell infusions following non-myeloablative HLA-haploidentical transplantation to augment graft-versus-tumor effects in patients with hematological malignancies.” NIH 2nd International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation Meeting, Nov 2012.
16. Thakar MS, Logan B, Pasquini M, McCarthy P, Ho V, Cooke K, Zhu X, Rizzo D, Sorror M. “The Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Can Prospectively Discriminate Risks Affecting Overall Survival in Pediatric and Adult Patients with Non-Malignant Diseases.” Blood (ASH Annual Meeting Abstracts), Dec 2012.
17. Robinson H, Nugent M, Simpson P, Keever-Taylor C, Margolis D, Casper J, Thakar M. “Long-Term Single Center DLI Outcomes Show A Role For Durable Response In High-Risk Pediatric Lymphoid Malignancies” Pediatric Blood and Marrow Transplant Consortium/American Society of Pediatric Hematology Oncology Annual Meeting Abstract April 2013.
18. Thakar MS, Walters M, Sandmaier BM, Storb R, Flowers ME, Deeg J, O’Donnell P, Woolfrey A, Kiem HP. “Long-Term Follow-Up of Cyclophosphamide-Based In Vivo T-Cell Depletion For HLA-Haploidentical Transplantation In Fanconi Anemia” Blood ASH Annual Meeting Abstracts ), Dec 2013.
19. Keever-Taylor CA, Jones LA, Heimfeld S, Sandmaier BM, Hari P, Thakar MS. “Characteristics of Products for NK Cell Infusion Prepared by CD3 Depletion Followed by CD56 Enrichment: Requirements for Rare Event Analysis” Cytotherapy April 2014 (Vol. 16, Issue 4,Page S19)
20. Vitola B, Thakar M, Basal D, 1, Szabo S, 1, Agni R, Veith R, Talano JA. Hemophagocytic Lymphoproliferative Histiocytosis (HLH) Mimicking Neonatal Hemochromatosis. North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Poster Presentation, Oct 2014.
21. Vitola B, Thakar M, Basal D, 1, Szabo S, 1, Agni R, Veith R, Talano JA. Hemophagocytic Lymphoproliferative Histiocytosis (HLH) Mimicking Neonatal Hemochromatosis. Annual Meeting of the Histiocyte Society, Oct 2014
22. Keever-Taylor, CA, Padmanabhan A, Hari P, Thakar MS. “A Novel Tool Using Marrow Natural Killer (NK) Cell Percentages to Predict Collection Requirements of Peripheral Blood Mononuclear Cell (MNC), Apheresis Products Used in NK Cell Adoptive Immunotherapy Blood ASH Annual Meeting Abstracts Dec 2015.